RT Journal Article
SR Electronic
T1 Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin–Paclitaxel: A Prospective Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3505
OP 3512
VO 37
IS 7
A1 TOMOYUKI OTSUKA
A1 TAKASHI NOJIRI
A1 SEIGO MINAMI
A1 HIROSHI HOSODA
A1 MUNEYOSHI KUROYAMA
A1 HARUHIKO HIRATA
A1 KAORI NAKANISHI
A1 SUGURU YAMAMOTO
A1 KIYOSHI KOMUTA
A1 KENJI KANGAWA
A1 TAKASHI KIJIMA
YR 2017
UL http://ar.iiarjournals.org/content/37/7/3505.abstract
AB Aim: To identify predictive markers for efficacy of combination bevacizumab and carboplatin-paclitaxel treatment in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients and Methods: Twenty patients received carboplatin (area under the concentration-time curve (AUC) 6 mg/ml×min) and paclitaxel (200 mg/m2) with bevacizumab (15 mg/kg) on day 1 of a 21-day cycle. After four cycles of induction therapy, patients received bevacizumab maintenance therapy until disease progression or unacceptable toxicity occurred. Plasma and serum samples (baseline, day 8 and before cycle 2) were analyzed for natriuretic peptide content. Results: Plasma brain natriuretic peptide (BNP) levels were significantly decreased at day 8 (20.1±4.0 pg/ml vs. 9.1±1.8 pg/ml, p=0.0002). Patients whose plasma BNP level was reduced to <50% of the baseline at day 8 had a longer progression-free survival (PFS) than those with a less decrease (9.73 versus 2.63 months, p=0.00013). In multivariate Cox analysis, decrease of plasma BNP concentration was associated with a longer PFS (p=0.0022). Conclusion: Decrease of plasma BNP concentration correlated with PFS after a treatment of combination bevacizumab plus carboplatin-paclitaxel.